Keywords: elderly, hypertension, HYVET, older adults, treatment Despite this, a trend analysis from the EWPHE trial suggested that the. The Hypertension in the Very Elderly Trial (HYVET) is a multicentre, open, randomised, controlled trial. The aim of this trial is to investigate the effect of active. Drugs Aging. ;18(3) Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Bulpitt C(1), Fletcher A, Beckett N, Coope J.

Author: Yozshubei Faunos
Country: Montenegro
Language: English (Spanish)
Genre: History
Published (Last): 18 December 2008
Pages: 419
PDF File Size: 19.7 Mb
ePub File Size: 14.97 Mb
ISBN: 401-7-23572-226-6
Downloads: 25046
Price: Free* [*Free Regsitration Required]
Uploader: JoJozahn

The number of subjects who smoked cigarettes 2. Usable articles Nephrology Cardiology Geriatrics. This treatment regimen was also found to be associated with a large and significant reduction in hyveet failure, whilst proving particularly efficacious in the management of isolated systolic hypertension.

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic trail. However, those who had reached either primary or secondary end points during the main trial apart from myocardial infarction, heart failure and skeletal fracture were excluded. The trial steering group also published an hjvet evaluating the association of depression with cardiovascular mortality and morbidity, all-cause mortality and incident hrial.

The investigators also observed a non-significant reduction in the primary outcome measure, stroke, unadjusted hazard ratio HR 0. Although the model requires further validation, it suggests that cognitive change in those aged over 80 years is small, depends on baseline cognitive function and the relative efficacy of anti-hypertensive treatment [ 25 ]. At 2 years there were no significant changes in serum potassium, uric acid, glucose and creatinine between the trial arms [ 13 ].

Hypertension In The Very Elderly Trial (HYVET): Lower Is Better, But Not Too Low

In looking at the presence or absence of previous cardiovascular disease, only triak and women out of the entire HYVET population trila any prior CVD. However, with the passage of time, a progressive effort has been made to expand the evidence base for treatment in older adults. Bulpitt or any of the other authors. But the co-Chair of the session, Dr Jan Staesson from Leuven Belgium warned that among patients with dementia there could be some whose reduced blood pressure was partly caused by brain lesions which disregulate blood pressure control, and that this might give a false indication of any risk of treatment.


Association of depression with subsequent mortality, cardiovascular morbidity and incident dementia in people aged 80 and over and suffering from hypertension. As a result, it remains unclear whether such benefits persist or diminish over a longer time course and although the inclusion criteria allowed for the enrolment of patients aged between 80 and years, most were 80 to 85 years old trual age; When the p value for trend with age was corrected for gender, there were still few significant differences from the overall population.

This article has been cited by other articles in PMC.

Further Results of the Hypertension in the Very Elderly Trial (HYVET)

At 2 years, there were no biochemical differences in serum potassium, uric acid, glucose, or creatinine, although Dr. Patients are to be randomised to 3 groups- i no treatment; ii treatment with a diuretic [bendroflumethiazide bendrofluazide ]; or iii treatment with an angiotensin converting enzyme ACE inhibitor lisinopril.

Treatment of hypertension in patients 80 years of age or older. Given this uncertainty, the Hypertension in the Very Elderly Trial HYVET was commissioned with an open label pilot undertaken to determine trial feasibility [ 1112 ].

With safety always an issue in the elderly, the combination therapy proved to be extremely safe: Those on antihypertensives at baseline had their medications stopped prior to placebo run-in.

Although waist circumference was not reported, hypertensive status was infrequently associated with other features of the metabolic syndrome in the trial population, hvyet from those hyvett who had suffered a prior cardiovascular event [ 17 ].

Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial.

Thus, the benefit of treatment above 85—90 years of age remains uncertain [ 1819 ]. However, at the time of the final intention-to-treat analysis in Octoberthis significant reduction in the primary outcome measure failed to show statistical triaal — the reasons for which have never been elaborated.


Conflict of interest statement All authors have completed the Unified Competing Interest form at http: Support Center Support Center. Mortality by race-sex and age. Dr Peter Sleight of Oxford in the UK asked whether this was related to cerebrovascular hyfet, but Dr Peters thought the sample size of patients in this group was insufficient to generate an answer from the HYVET data.

Thus, social and economic status were not adequately controlled for and reverse causality could not be excluded. This hypothesis, that indapamide a thiazide-like diuretic reduces urinary calcium excretion and as a result may reduce fracture rates, was tested in a sub-study. Hypertension — treated and untreated.

Thus, no significant difference trual observed between the two trial arms HR 0. Bulpitt noted, the number needed to treat was very low to prevent cardiovascular events: In addition, it was notable that four centres closed in the first year due to data quality issues [ 13 ]. Subjects were then randomized to one of two treatment arms, the thiazide like diuretic, indapamide sustained release, 1.

In common with many other clinical trials in older people, the inclusion criteria also required that subjects be in relatively good physical and mental health individuals with dementia and those resident in nursing homes were excludedquestioning the applicability of the trial outcomes to the real life setting [ 1316 ].

The optimal target BP among very elderly patients has yet to be defined.